PharmTech's May 2026 Regulatory Roundup covers the FDA's launch of one-day inspections, Elsa 4.0 AI upgrade, and final CMC flexibility guidance for cell and gene therapies — which Samsung Biologics' Abigail De La Pena Garcia called "a significant step forward" formalizing a "more flexible and scientifically driven regulatory approach."
Read the full roundup for a complete breakdown of the month's regulatory developments.
PharmTech's May 2026 Regulatory Roundup covers the FDA's launch of one-day inspections, Elsa 4.0 AI upgrade, and final CMC flexibility guidance for cell and gene therapies — which Samsung Biologics' Abigail De La Pena Garcia called "a significant step forward" formalizing a "more flexible and scientifically driven regulatory approach."
Read the full roundup for a complete breakdown of the month's regulatory developments.
Share article
Related Content